CLLS

Cellectis S.A. CLLS

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,683 of 2,925

Why it scores 24Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$72.95M

Quarter to Dec 31

Net income

$-67.59M

Quarter to Dec 31

Free cash flow

$-41.76M

Quarter to Dec 31

Operating margin

-45.3%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$28.45M total
B Group, Inc.
$9.84M0.0%
Long Focus Capital Management, LLC
$8.23M-0.1%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$7.93M-16.8%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$681.0K0.0%
BlackRock, Inc.
$676.3K-34.0%
MORGAN STANLEY
$256.4K-1.5%
LPL Financial LLC
$253.2K+0.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$151.4K-23.5%
BNP PARIBAS FINANCIAL MARKETS
$120.3K-2.2%
UBS Group AG
$101.8K+13.9%
Delaney Dennis R
$72.0K0.0%
RHUMBLINE ADVISERS
$43.0K-5.0%
XTX Topco Ltd
$36.8K-24.5%
HARBOUR INVESTMENTS, INC.
$13.5K0.0%
NATIONAL BANK OF CANADA /FI/
$10.8K0.0%
WELLS FARGO & COMPANY/MN
$9.4K0.0%
ROYAL BANK OF CANADA
$5.0KNew
Union Bankshares Corp
$4.5K0.0%
Allworth Financial LP
$1.5K0.0%
POM Investment Strategies, LLC
$1.5K0.0%
GAMMA Investing LLC
$1.4K-36.9%
OSAIC HOLDINGS, INC.
$3000.0%
Larson Financial Group LLC
$2250.0%
Caitong International Asset Management Co., Ltd
$147New
JONES FINANCIAL COMPANIES LLLP
$142New
See all 27 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CLLS

Earnings Per Share

13fpro.ai/company/CLLS

Loading ratio trend…

CLLS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cellectis S.A.'s annual filings on SEC EDGAR.

Cellectis S.A. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$72.9M$-67.6M-45.3%
FY 2024$41.5M$-36.8M-143.5%
FY 2023$755.0K$-101.1M—
FY 2022$19.2M$-106.1M—
FY 2021$30.3M$-114.2M—
FY 2020$51.1M$-81.1M-82.9%
Source: CLLS filings on SEC EDGAR →

Companies similar to CLLS

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

About Cellectis S.A. (CLLS): stock profile, AI score and financials

Cellectis S.A. (CLLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLLS at 23.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,683 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Cellectis S.A. reports quarterly revenue of $72.9M, net income of $-67.6M, an operating margin of -45.3%. Top institutional holders of CLLS by reported 13-F value include B Group, Long Focus Capital Management, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME, based on the most recent SEC filings. CLLS trades on the Nasdaq exchange and files with the SEC under CIK 1627281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellectis S.A. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1627281 →